Editas Medicine (EDIT) vs ARS Pharmaceuticals (SPRY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Editas Medicine (EDIT) has outperformed ARS Pharmaceuticals (SPRY) over the past year, losing 30.0% versus a loss of 57.8%. Over five years, SPRY leads with a -55.8% price change compared with -92.8% for EDIT. ARS Pharmaceuticals is the larger company by market cap ($433.6 million vs $422.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EDIT | SPRY |
|---|---|---|
| Share price | $2.75 | $4.36 |
| Market cap | $422.35M | $433.59M |
| 1-day change | +0.73% | +1.51% |
| YTD return | +34.15% | -62.58% |
| 1-year return | -30.03% | -57.79% |
| 5-year return | -92.77% | -55.78% |
| EPS (TTM) | $-0.68 | $-2.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.33 | $13.15 |
| 52-week low | $1.66 | $3.99 |
| Distance from 52-week high | -36.49% | -66.84% |
| Analyst consensus | buy | none |
| Avg. price target upside | +114.55% | +416.06% |
| Average volume | 2.48M | 1.86M |
| Shares outstanding | 153.58M | 99.45M |
| Employees | 87 | 195 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EDIT has outperformed SPRY by 27.8 percentage points over the past year.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Healthcare · Biotechnology · 87 employees
About ARS Pharmaceuticals
SPRY stock →ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis.
Healthcare · Biotechnology · 195 employees
EDIT vs SPRY FAQ
Which is bigger, Editas Medicine or ARS Pharmaceuticals?
ARS Pharmaceuticals (SPRY) is larger, with a market capitalization of $433.59M compared with $422.35M for Editas Medicine (EDIT).
Which stock has performed better over the past year, EDIT or SPRY?
EDIT returned -30.03% over the past 12 months, compared with -57.79% for SPRY (price return, excluding dividends). Past performance does not predict future results.
Are Editas Medicine and ARS Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.